uniQure selloff on AMT-130 update ‘appears overdone,’ says H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio notes uniQure shares are lower after the company reported an interim data update on a Phase 1/2 trial in the U.S. evaluating gene therapy AMT-130 in patients with Huntington’s disease. The firm believes that investors have been disappointed by the apparent lack of target engagement as measured by mutant huntingtin protein, or mHTT, particularly at the high dose, but it views the selloff as one that “appears overdone.” The pullback presents a buying opportunity for investors to position for potential advancement of AMT-130, as well as advancement of the early-stage pipeline, contends the firm, which has a Buy rating and $90 price target on uniQure.